Mesoblast (NASDAQ: MESO) Acquires CAR Platform Technology to Enhance Cell Products
Expert Analysis Mesoblast (NASDAQ: MESO) has taken a significant step forward by securing an exclusive global license to a patented chimeric antigen receptor (CAR) technology platform. This move highlights the company’s strategic intent to refine and enhance its allogeneic cellular therapies using advanced engineering techniques. The integration of CAR technology in mesenchymal lineage stromal cells (MSCs) is expected to elevate the precision and effectiveness of treatments, potentially transforming outcomes for…









